Aclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion, Inc. (Nasdaq: ACON) said the USPTO issued a Notice of Allowance for a patent application covering “Multi-Voxel Prescription for Lumbar Disc Evaluation,” aimed at improving MR spectroscopy voxel positioning in its Nociscan workflow. The company said the claims are intended to reduce repeat scans and variability across sites, extending its IP portfolio of 65+ patents worldwide.

Original reporting
Published Aug 12, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ACON
Bullish
medium confidence
Mentioned
$ACON
Relevance
5/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The USPTO Notice of Allowance covers scan-prescription methods to improve voxel placement accuracy, aiming to reduce trial-and-error, repeat scans, and variability across imaging sites.

02

Market read

This is a tangible IP milestone for Aclarion’s MR spectroscopy scan-prescription workflow, but the release does not quantify financial impact or adoption changes.

03

What to watch

Investors may discount the news if Nociscan adoption metrics, reimbursement, or competitive differentiation are unchanged; the release also lacks details on expected timeline to issuance or enforcement strategy.

Relevance 5/10Novelty 6/10Timing: today’s patent allowance headline for Aclarion

Background

Aclarion’s Nociscan is a SaaS platform using MR spectroscopy and analytics to help localize chronic low back pain discs.

Company-level read

Ticker impact

$ACONBullishMedium confidence
Context

Aclarion announced USPTO issued a Notice of Allowance for a patent covering multi-voxel prescription for lumbar disc MR spectroscopy in Nociscan.

Expected impact

Near-term impact likely modest unless investors view it as a meaningful step toward commercialization scale or licensing leverage.

Evidence & confidence

The disclosure is a concrete regulatory milestone (Notice of Allowance), but it does not include financial terms, revenue impact, or issuance timing beyond “once issued.”

Market effects

Highlights defensibility in MR spectroscopy workflow software, which may support investor appetite for imaging AI platforms with IP-protected acquisition pipelines.

No clear regional read-through beyond US-listed healthcare tech sentiment.

Limited global impact; patent coverage is described as worldwide (issued and pending), but no international commercialization update is provided.

Counterpoint

A Notice of Allowance is not the same as an issued patent, and the article provides no evidence of near-term revenue uplift from the claim scope.

Key entities

  • Aclarion, Inc.

    Nasdaq-listed healthcare technology company marketing Nociscan and building IP around MR spectroscopy acquisition and analytics.

  • USPTO

    US Patent and Trademark Office that issued the Notice of Allowance for Aclarion’s patent application.

  • Nociscan

    Aclarion’s MR spectroscopy-based SaaS workflow for lumbar disc evaluation.

Related articles

$ACONMedAI 8/10

Aclarion Updates CLARITY Enrollment Criteria, Keeps Trial Timeline On Track

Aclarion (ACON) revised its CLARITY trial enrollment criteria to expand the patient pool and accelerate enrollment, while maintaining scientific rigor. The changes were approved by most trial sites and are expected to improve enrollment consistency and real-world applicability. The company anticipates providing an enrollment update by year-end 2026, with the trial timeline remaining unchanged. ACON's stock closed at $2.35, up 2.40%.

$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.

$GOOGMedAI 8/10

Google’s expansion puts Wyoming’s data center debate in focus

Google plans a $17 billion data center in Wyoming, committing to cover electricity costs and using air cooling to reduce water use. The project includes a 702-MW fuel cell facility powered by natural gas, with carbon capture technology. Local residents have raised concerns about resource use and long-term impacts, while Google estimates hundreds of millions in property tax revenue for the area. Construction is expected to take several years, with full operation by 2028.

$MRNAMedAI 8/10

A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and…

A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and hospitalization risk by 47.0% compared to Pfizer/BioNTech's BNT162b2 in older veterans during the 2025-2026 season. The study included 294,499 participants, with mRNA-1283 showing better outcomes across various metrics. Moderna supported the study, which was conducted by independent investigators.